Evotec SE ADR Dossier
Qualitative Analysis
Business overview
Evotec SE is a global drug discovery and development company headquartered in Hamburg, Germany. The company operates through two primary segments: Discovery & Preclinical Development (D&PD) and Just – Evotec Biologics (JEB). Evotec leverages advanced technologies, including artificial intelligence (AI), machine learning, and high-throughput screening, to provide integrated contract research organization (CRO) services, standalone R&D programs, and strategic partnerships to major pharmaceutical and biotechnology companies, academic institutions, and venture capital firms.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A multi-stage transformation initiative designed to streamline operations, reduce complexity, and establish a more agile operating model built across three pillars: operational excellence, scientific leadership, and commercial execution.
Expected impact: Reduction of global footprint from 14 sites to 10, workforce adjustments affecting up to 800 positions, and the realization of approximately €75 million in annualized run-rate savings by the end of 2027.
Transitioning the Just – Evotec Biologics division to an asset-lighter and capital-efficient business model to improve margins and leverage proprietary technology and IP.
Expected impact: Allows Evotec to retain short-, mid-, and long-term economic upside through licensing, milestones, and royalties while transferring heavy manufacturing assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Evolves the multi-year strategic partnership by transitioning the Toulouse J.POD facility to Sandoz while granting Sandoz access to Just – Evotec Biologics' continuous manufacturing platform.
Terms: Sandoz agreed to acquire Just – Evotec Biologics EU SAS (Toulouse site) for €350 million ($380 million) in cash, with Evotec retaining future development revenues, milestones, and product royalties.
Monetization of Evotec's minority stake in Tubulis following Gilead's acquisition of Tubulis.
Terms: Evotec agreed to receive approximately $100 million upfront in cash, plus up to $58 million in potential future milestones.
Advancing tuberculosis drug discovery programs and AI-driven antibody developability.
Terms: Multiple grants awarded to support discovery programs.